Review ARTICLE

Front. Oncol., 24 March 2014 | doi: 10.3389/fonc.2014.00047

Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment

  • 1Department of Neuropathology, Frenchay Hospital, Bristol, UK
  • 2Department of Neuropathology, University of Michigan, Ann Arbor, MI, USA

It is increasingly clear that both adult and pediatric glial tumor entities represent collections of neoplastic lesions, each with individual pathological molecular events and treatment responses. In this review, we discuss the current prognostic biomarkers validated for clinical use or with future clinical validity for gliomas. Accurate prognostication is crucial for managing patients as treatments may be associated with high morbidity and the benefits of high risk interventions must be judged by the treating clinicians. We also review biomarkers with predictive validity, which may become clinically relevant with the development of targeted therapies for adult and pediatric gliomas.

Keywords: gliomas, prognostic biomarkers, predictive biomarkers

Citation: Haynes HR, Camelo-Piragua S and Kurian KM (2014) Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Front. Oncol. 4:47. doi: 10.3389/fonc.2014.00047

Received: 26 January 2014; Accepted: 27 February 2014;
Published online: 24 March 2014.

Edited by:

Andreas Hoeflich, Leibniz-Institute for Farm Animal Biology, Germany

Reviewed by:

Federica Barbieri, University of Genova, Italy
Peter F. Ambros, Children’s Cancer Research Institute, Austria
Carl Friedrich Classen, University Children’s Hospital, Rostock, Germany

Copyright: © 2014 Haynes, Camelo-Piragua and Kurian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Kathreena M. Kurian, Brain Tumor Research Group, Institute of Clinical Neurosciences, Frenchay Hospital, Frenchay Park Road, Bristol BS16 1LE, UK e-mail: kathreena.kurian@nbt.nhs.uk

Back to top